Bruker Corporation $BRKR Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 134.5% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 99,173 shares of the medical research company’s stock after purchasing an additional 56,880 shares during the period. SG Americas Securities LLC’s holdings in Bruker were worth $4,672,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BRKR. Allworth Financial LP raised its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Spire Wealth Management boosted its position in Bruker by 85.3% during the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after purchasing an additional 665 shares during the period. Jones Financial Companies Lllp increased its holdings in Bruker by 79.7% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock valued at $86,000 after purchasing an additional 1,230 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock valued at $114,000 after purchasing an additional 942 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in Bruker by 9,800.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 4,851 shares of the medical research company’s stock valued at $158,000 after purchasing an additional 4,802 shares during the period. Institutional investors and hedge funds own 79.52% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a research report on Wednesday, December 10th. JPMorgan Chase & Co. raised their target price on Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Guggenheim decreased their price target on Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a report on Monday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Friday, March 27th. Finally, UBS Group reiterated a “neutral” rating and set a $49.00 price objective on shares of Bruker in a research note on Friday, February 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $49.77.

Bruker Stock Down 0.1%

Shares of Bruker stock opened at $36.08 on Thursday. The business has a 50-day moving average of $39.18 and a 200-day moving average of $41.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The company has a market capitalization of $5.49 billion, a PE ratio of -240.53, a P/E/G ratio of 2.16 and a beta of 1.20. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $56.22.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing the consensus estimate of $0.65 by ($0.06). The business had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company’s revenue was down .2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s dividend payout ratio is presently -133.33%.

Insider Activity at Bruker

In other news, VP Mark Munch sold 7,000 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 11,000 shares of company stock worth $554,280. Corporate insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.